Analyst firms · Morgan Stanley · AARD

Morgan Stanley AARD price target and rating history

Aardvark Therapeutics Inc. (AARD) · Health Care

Morgan Stanley rates Aardvark Therapeutics Inc. (AARD) Underweight with a $3 price target, as of its latest action on May 15, 2026. It has published 3 rating actions on AARD since March 2025, including 0 upgrades and 2 downgrades. Across 6 firms with a AARD price target in the last 12 months, the median target is $19. Morgan Stanley's $3 is 84% below that.

Current rating
Underweight
Price target
$3
Median target, all firms
$19
Actions on AARD
3

Morgan Stanley price target on AARD

$29$16$32026
Morgan Stanley price target on AARD, each point a stated target, March 2025 to May 2026.

Every Morgan Stanley rating on AARD

How other firms rate AARD

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Raymond JamesMkt Perform$47Nov 5, 2026
Morgan StanleyUnderweight$3May 15, 2026
StifelHold$6Mar 2, 2026
RBC Capital MarketsSector Perform$6Mar 2, 2026
H.C. WainwrightNeutralMar 2, 2026
B. Riley SecuritiesBuy$32Jan 28, 2026
OppenheimerOutperform$35Dec 23, 2025
William BlairOutperformDec 12, 2025

Questions about Morgan Stanley and AARD

What is Morgan Stanley's price target for AARD?
Morgan Stanley's latest stated price target for Aardvark Therapeutics Inc. (AARD) is $3, from its action on May 15, 2026.
What is Morgan Stanley's rating on AARD?
Morgan Stanley rates AARD Underweight, a bearish rating, as of May 15, 2026.
When did Morgan Stanley last change its view on AARD?
On May 15, 2026, Morgan Stanley downgrades to Underweight from Equal-Weight, price target $3.
How does Morgan Stanley's AARD target compare with other analysts?
Across 6 firms with a AARD price target in the last 12 months, the median target is $19. Morgan Stanley's $3 is 84% below that.

All Morgan Stanley ratingsAARD news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.